



PREDICT RESPONSE BEFORE TREATMENT BEGINS

One patient's cancer may respond to temozolomide (TMZ) when another's won't. So why would you use a one-size-fits-all approach? Predict response and tailor a treatment that *works* using Kiyatec's 3D Predict™ platform, clinically and analytically validated in our CLIA-certified laboratory.



Live tumor cell 3D spheroids are created in up to 1000 individual microenvironments per patient. They are then exposed directly to 12 therapeutic agents.




The patient's tumor's response to cancer therapies is examined.




Patient tumor-specific therapeutic response evidence is delivered within 7-10 days.

TMZ Responders Experienced an Overall Survival Benefit¹



- In a study on the prospective prediction of clinical drug response in high-grade gliomas (HGG) using 3D Predict, clinical response/nonresponse to temozolomide was accurately predicted in 85% ($p = .007$) of newly diagnosed patients within 7 days of surgery, prior to treatment.¹
- **Patients receiving therapy demonstrated a median overall survival of 11.6 months for responders vs 5.9 for nonresponders.¹**


Clinical outcomes in HGG have remained relatively unchanged over the last 3 decades with only modest increases in overall survival.¹ **3D Predict is here to change that.**



3D PREDICT

IS REVOLUTIONIZING CANCER CARE

Kiyatec's *ex vivo* 3D cell culture platforms utilize patients' live cancer cells from standard of care surgical procedure to create patient-specific, *in vivo*-like tumor and immune microenvironments, outside the body, to accurately model and assess response to investigational and FDA-cleared cancer therapies.

	 3D Predict™ Glioma	Status Quo Testing
WHAT IT IS	Functional precision oncology	NGS, gene expression, biomarkers, AI
WHAT IS MEASURED	Clinically meaningful measurement of the interaction of live cells with drugs	Static attribute measured from or calculated from nonliving tissue
HOW A DRUG IS SELECTED	Evidence based on patient's own cancer cell death rate	Historical probability based on past results from relevant population
CLINICAL IMPACT	Better information (evidence vs probability) for more personalized matching, leading to higher response rates to cancer drugs	Patients frequently do not match nor respond to test-indicated cancer drugs

Assess response to 12 top chemotherapy agents:

- Abemaciclib
- Dabrafenib
- Everolimus
- Lomustine
- Procarbazine
- Temozolomide
- Carboplatin
- Etoposide
- Irinotecan
- Osimertinib
- Rucaparib
- Trametinib



Every body is unique and their cancer treatment should be too.
 Predict response with 3D Predict before treatment begins. Visit [Kiyatec.com](https://kiyatec.com) or contact us at info@kiyatec.com for more information.

Reference: 1. Shuford S, Lipinski L, Abad A, et al. Prospective prediction of clinical drug response in high-grade gliomas using an *ex vivo* 3D cell culture assay. *Neurooncol Adv.* 2021;3(1).

